<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001127.v1.p1" parentStudy="phs001127.v1.p1" createDate="2016-05-20" modDate="2016-05-20">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigator</td><td>Rameen Beroukhim, MD, PhD</td><td>Dana-Farber Cancer Institute, Boston, MA, USA, Brigham and Women&#39;s Hospital, Boston, MA, USA, Broad Institute of MIT and Harvard, Cambridge, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Scott L Carter, PhD</td><td>Dana-Farber Cancer Institute, Boston, MA, USA, Harvard Chan School of Public Health, Boston, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>William J Gibson, PhD</td><td>Dana-Farber Cancer Institute, Boston, MA, USA, Broad Institute of MIT and Harvard, Cambridge, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Erling Hoivik, PhD</td><td>University of Bergen, Bergen, Norway</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Analysis of Paired Endometrial Cancer Primaries and Metastases</StudyNameEntrez>
	<StudyNameReportPage>Genomic Analysis of Paired Endometrial Cancer Primaries and Metastases</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Formation of metastases is the major cause of cancer related deaths. Recent studies have sequenced primary endometrial carcinomas yielding data for a single entity in the progression from the birth of a progenitor tumor cell to metastatic disease. However, the progression of these tumors to metastases has not been characterized. We performed whole-exome sequencing of 98 tumor biopsies including complex atypical hyperplasias, primary tumors and paired abdominopelvic metastases to survey the evolutionary landscape of endometrial cancer. We expanded and reanalyzed TCGA-data, identifying novel recurrent alterations in primary tumors, including mutations in the estrogen receptor cofactor <i>NRIP1</i> in 12% of patients. We found that likely driver events tended to be shared by primary and metastatic tissue-samples, with notable exceptions such as <i>ARID1A</i> mutations. Phylogenetic analyses in cases with multiple metastases indicated these metastases typically arose from one lineage of the primary tumor. These data indicate extensive genetic heterogeneity within endometrial cancers and relative homogeneity across metastatic sites.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The study included women with abdominopelvic metastasis of endometrial cancer and paired biopsies of the primary tumor.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Gibson WJ, Hoivik EA, et al." title="The genomic evolution of endometrial carcinoma progression and abdominopelvic metastasis and the identification of novel recurrent mutations." journal="Nature Genetics, revised March 2016"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Endometrial Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasm Metastasis"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigator">
			<AttName>Rameen Beroukhim, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA, Brigham and Women&#39;s Hospital, Boston, MA, USA, Broad Institute of MIT and Harvard, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Scott L Carter, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA, Harvard Chan School of Public Health, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>William J Gibson, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA, Broad Institute of MIT and Harvard, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Erling Hoivik, PhD</AttName>
			<Institution>University of Bergen, Bergen, Norway</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA-MDS" longName="Disease-Specific (Cancer, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001127.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001127.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001127.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
